<strong>Advances of Targeted Drug Delivery Based on PEG-PCL</strong>

Abstract

Abstract:In recent years，biodegradable materials have been widely used in pharmaceutical field because of the excellent biodegradability，biocompatibility and mechanical property. Among them，poly（ethylene glycol）-poly（ε-caprolactone） copolymers （PEG-PCL） has been widely used in drug delivery system. The drug delivery system based on PEG-PCL can be modified with various ligands，such as peptides，antibodies，carbohydrates，aptamers and small molecules for enhancing the bioavailability and therapeutic effect，achieving targeted drug delivery. In this paper，the research progress of targeted drug delivery based on PEG-PCL is reviewed，in order to provide ideas and methods for the applications of PEG-PCL in targeted drug delivery system.

Key words:poly（ethylene glycol）-poly（&,epsilon,-caprolactone） copolymers （PEG-PCL）,targeted,drug delivery system

SU Xiao-mei，ZHANG Dan-shen.Advances of Targeted Drug Delivery Based on PEG-PCL[J]. Acta Neuropharmacologica, 2016, 6(5): 22-28.

References

[1] Eric A Bleeker, Wim H de Jong, Robert Geertsma, et al. Considerations on the EU de?nition of a nanomaterial: science to support policy making[J]. Regul Toxicol Pharmacol, 2013, 65(1): 119-125.

[2] Daniel Bobo, Kye J Robinson, Jiaul Islam, et al. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date[J]. Pharm Res, 2016, 33(10): 2373-2387.

[3] Andreas Wicki, Dominik Witzigmann, Vimalkumar Balasubramanian, et al. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications[J]. J Contro Release, 2015, 200: 138-157.

[4] Wu Xue-ping, Wang Chi. Advances in peptide-modified liposome targeted drug delivery system[J]. Chin J Mod Appl Pharm, 2010, 27(8): 681-685.

[5] Rashmi Prabhu, Vandana B Patravale, Medha D Joshi. Polymeric nanoparticles for targeted treatment in oncology: current insights[J]. Int J Nanomedicine, 2015, 2015(10): 1001-1018.

[6] Hossein Danafar, Soodabeh Davaran, Kobra Rostamizadeh, et al. Biodegradable m-PEG/PCL core-shell micelles: preparation and characterization as a sustained release formulation for curcumin[J]. Adv Pharm Bull, 2014, 4(2): 501-10.

[7] Dong Xia, Wei Chang, Lu Li, et al. Fluorescent nanogel based on four-arm PEG-PCL copolymer with porphyrin core for bioimaging[J]. Mater Sci Eng C Mater Biol Appl, 2016, 61:214-9.

[8] Zhou Jun-li, Ni Rong, Chau Ying. Polymeric vesicle formation via temperature-assisted nanoprecipitation[J]. RSC Advances, 2017, 7(29): 17997-18000.

[9] A Al Samadab, Bethrya A, Koziolovác E, et al. PCL-PEG graft copolymers with tunable amphiphilicity as efficient drug delivery systems[J]. J Mater Chem B, 2016, 4(37): 6228-6239.

[10] Yuichi Ohya, Shinya Takeda, Yosuke Shibata, et al. Evaluation of polyanion-coated biodegradable polymeric micelles as drug delivery vehicles[J]. J Control Release, 2011, 155(1): 104-110.

[11] Xin Hong-liang, Jiang Xin-yi, Gu Ji-jin, et al. Angiopep-conjugated poly(ethyleneglycol)- co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma[J]. Biomaterials, 2011, 32(18): 4293-4305.

[12] Xin Hong-liang, Sha Xian-yi, Jiang Xin-yi, et al. Anti-glioblastoma e?cacy and safety of paclitaxel-loading angiopep-conjugated dual targeting PEG-PCL nanoparticles[J]. Biomaterials, 2012, 33(32): 8167-8176.

[13] Huang Rong-qin, Ke Wei-lun, Liu Yang, et al. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain[J]. Biomaterials, 2008, 29(2): 238-246.

[14] Dominique Legrand, Annick Pierce, Elisabeth Elass, et al. Lactoferrin structure and functions[J]. Adv Exp Med Biol, 2008, 606: 163-194.

[15] Liu Zhong-yang, Jiang Meng-yin, Kang Ting, et al. Lactoferrin-modi?ed PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration [J]. Biomaterials, 2013, 34(15): 3870-3881.

[16] Takanori Kanazawa, Ken Sugawara, Ko Tanaka, et al. Suppression of tumor growth by systemic delivery of anti-VEGF siRNA with cell-penetrating peptide-modified MPEG-PCL nanomicelles[J]. Eur J Pharm Biopharm, 2012, 81(3): 470-477.

[17] Ko Tanaka, Takanori Kanazawa, Yasunori Shibata, et al. Development of cell-penetrating peptide-modified MPEG-PCL diblock copolymeric nanoparticles for systemic gene delivery[J]. Int J Pharm, 2010, 396(1-2): 229-238．

[18] Ko Tanaka, Takanori Kanazawa, Shogo Horiuchi, et al. Cytoplasm-responsive nanocarriers conjugated with a functional cell-penetrating peptide for systemic siRNA delivery[J]. Int J Pharm, 2013, 455(1-2): 40-47.

[19] Amitava Mitra, Justin Mulholland, Anjan Nan, et al. Targeting tumor angiogenic vasculature using polymer-RGD conjugates[J]. J Control Release, 2005, 102(1): 191-201.

[20] Yang Jian-hong, Hou Yan-hui, Ji Gang-jian, et al. Targeted delivery of the RGD-labeled biodegradable polymersomes loaded with the hydrophilic drug oxymatrine on cultured hepatic stellate cells and liver fibrosis in rats[J]. Eur J Pharm Sci, 2014, 52: 180-190.

[21] Zhu Ya-yin, Zhang Jian, Meng Feng-hua, et al. cRGD-functionalized reduction-sensitive shell-sheddable biodegradable micelles mediate enhanced doxorubicin delivery to human glioma xenografts in vivo[J]. J Control Release, 2016, 233: 29-38.

[22] Alyssa M Master, Qi Yi-zhi, Nancy L Oleinick, et al. EGFR-mediated intracellular delivery of Pc 4 nanoformulation for targeted photodynamic therapy of cancer: in vitro studies[J]. Nanomedicine, 2012, 8(5): 655-664.

[23] Master A M, Livingston M, Oleinick N L, et al. Optimization of a nanomedicine -based silicon phthalocyanine 4 photodynamic therapy (Pc 4-PDT) strategy for targeted treatment of EGFR-overexpressing cancers[J]. Mol Pharm, 2012, 9(8): 2331-2338.

[24] Yao Xing-lei, Yasuo Yoshioka, Ruan Gui-xin, et al. Optimization and internalization mechanisms of PEGylated adenovirus vector with targeting peptide for cancer gene therapy[J]. Biomacromolecules, 2012, 13(8): 2402-2409.

[25] Hu Quan-yin, Gao Xiao-ling, Kang Ting, et al. CGKRK-modi?ed nanoparticles for dual-targeting drug delivery to tumor cells and angiogenic blood vessels[J]. Biomaterials, 2013, 34(37): 9496-9508.

[26] Jacqueline Trotter, Khalad Karram, Akiko Nishiyama. NG2 cells: properties, progeny and origin[J]. Brain Res Rev, 2010, 63(1-2): 72-82.

[27] Jacqueline Trotter. NG2-positive cells in CNS function and the pathological role of antibodies against NG2 in demyelinating diseases[J]. J Neurol Sci, 2005, 233(1-2): 37-42.

[28] Chi Yong-bin, Zhu Shan-shan, Wang Chao, et al. Glioma homing peptide-modified PEG-PCL nanoparticles for enhanced anti-glioma therapy[J]. J Drug Target, 2016, 24(3): 224-232.

[29] Mishima K, Tsukikawa H, Miura I, et al. Ameliorative effect of NC-1900, a new AVP4-9 analog, through vasopressin V1A receptor on scopolamine-induced impairments of spatial memory in the eight-arm radial maze[J]. Neuropharmacology, 2003, 44(4): 541-552.

[30] Tomoko Tanaka, Kiyofumi Yamada, Kouji Senzaki, et al. NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory de?cits induced by b-amyloid protein in rats[J]. Eur J Pharmacol, 1998, 352(2-3): 135-142.

[31] Pang Zhi-qing, Lu Wei, Gao Hui-le, et al. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26[J]. J Control Release, 2008, 128(2): 120-127.

[32] Zou Tao, Fatimata Dembele, Anne Beugnet, et al. Nanobody-functionalized PEG-b-PCL polymersomes and their targeting study[J]. J Biotechnol, 2015, 214: 147-155.

[33] Philip Grossen, Gabriela Québatte, Dominik Witzigmann, et al. Functionalized solid-sphere PEG-b-PCL nanoparticles to target brain capillary endothelial cells in vitro[J]. J Nanomater, 2016, 2016: 1-13.

[34] Awesh Kumar Yadav, Pradeep Mishra, Sanyog Jain, et al. Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin[J]. J Drug Target, 2008, 16(6): 464-478.

[35] Yang Rui, Meng Feng-hua, Ma Shou-bao, et al. Galactose-decorated crosslinked biodegradable poly(ethylene glycol)-b-poly(ε-caprolactone) block copolymer micelles for enhanced hepatoma-targeting delivery of paclitaxel[J]. Biomacromolecules, 2011, 12 (8): 3047-3055.

[36] Tai Wan-yi, Ravi S Shukla, Qin Bin, et al. Development of a peptide-drug conjugate for prostate cancer therapy[J]. Mol Pharm, 2011, 8(3): 901-912.

[37] Alcides Chaux, John Eifler, Sarah Karram, et al. Focal positive prostate-specific membrane antigen (PSMA) expression in ganglionic tissues associated with prostate neurovascular bundle: Implications for novel intraoperative PSMA-based fluorescent imaging techniques[J]. Urol Oncol, 2011, 31(5): 572-575.

[38] Kristina W Thiel, Paloma H Giangrande. Intracellular delivery of RNA-based therapeutics using aptamers[J]. Ther Deliv, 2010, 1(6):849-861.

[39] Zhao Yun-qi, Duan Shao-feng, Zeng Xing, et al. Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells[J]. Mol Pharm, 2012, 9(6): 1705-1716.

[40] Teng Yun, Allicia C Girvan, Lavona K Casson, et al. AS1411 alters the localization of a complex containing protein arginine methyl-transferase 5 and nucleolin[J]. Cancer Res, 2007, 67(21): 10491-10500.

[41] Li Jing-wei, Feng Liang, Fan Li, et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides[J]. Biomaterials, 2011, 32(21): 4943-4950.

[42] Gao Hui-le, Qian Jun, Cao Shi-jie, et al. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles[J]. Biomaterials, 2012, 33(20): 5115-5123.

[43] Shefali Sabharanjak, Satyajit Mayor. Folate receptor endocytosis and trafficking[J]. Adv Drug Deliv Rev, 2004, 56(8): 1099-1109.

[44] Chrystalleni Lazarou, Margarita Kapsou. The role of folic acid in prevention and treatment of depression: an overiew of existing evidence and implications for practice[J]. Complement Ther Clin Pract, 2010, 16(3): 161-166.

[45] Yu Hong-liang, Chen Jiao, Liu Sen, et al. Enzyme sensitive, surface engineered nanoparticles for enhanced delivery of camptothecin[J]. J Control Release, 2015, 216: 111-120.

[46] Yang X, Deng W, Fu L, et al. Folate-functionalized polymeric micelles for tumor targeted delivery of a potent multidrug-resistance modulator FG020326[J]. J Biomed Mater Res A, 2008, 86(1): 48-60.

[47] Jae Sung Lee, William L Murphy. Functionalizing calcium phosphate biomaterials with antibacterial silver particles [J]. Adv Mater, 2013, 25(8): 1173-1179.

[48] Xiong Wei, Peng Li-xia, Chen Hong-bo. Surface modi?cation of MPEG-b-PCL-based nanoparticles via oxidative self-polymerization of dopamine for malignant melanoma therapy[J]. Int J Nanomedicine, 2015, 10: 2985-2996.

[49] Gu G, Xia H, Hu Q, et al. PEG-co-PCL nanoparticles modi?ed with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy[J]. Biomaterials, 2013, 34 (1): 196-208.

Advances of Targeted Drug Delivery Based on PEG-PCL

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles2

Recommended Articles

Metrics

[1]	REN Jing，ZHANG Dan-shen.Progress in Research of Brain Targeting Ligand for Nano-scale Drug Delivery Systems[J]. Acta Neuropharmacologica, 2017, 7(4): 17-25.
[2]	ZHANG Dan-shen, MEI Yan-fei, SONG Xiao-min, ZHUANG Zhong-bao, XUE Gui-ping.Study on the Distribution and Drug Releasing in Digestive Tract of Colon-Targeted Pellets ofRhubarbin Rats[J]. Acta Neuropharmacologica, 2015, 5(5): 20-27.